NCT07445074NARecruiting
AI-Based Mobile Intervention on Medication Non-Adherence and Transition
University of Central Florida
Start Date
5/1/2026
Completion Date
12/1/2026
Summary
This study aims to examine whether the AI-personalized version of the Medilepsy® app is more effective than the non-AI (standard version without AI personalization) can improve key outcomes, such as medical adherence and transition readiness, among underserved adolescents and young adults with epilepsy, ages 14-24, in Florida, USA. Outcomes are organized into primary (effectiveness), secondary (usability), and exploratory (language experience) endpoints.
Eligibility Criteria
Age Range: 14 years to 24 years
Inclusion Criteria:
* Diagnosed with epilepsy
* Currently prescribed anti-seizure medicine (ASMs)
* Identified as part of an underserved population, defined as meeting at least one of the following: member of a racial or ethnic group historically underrepresented in research or healthcare or low-income status (e.g., eligible for public assistance or government-subsidized health coverage)
* Are between 14-17 years old and able to provide assent, with a parent or LAR present to receive app notifications throughout the study
* Are between 18-24 years old and able to provide informed consent
* Able to read, speak, and write in English
* Resides in Florida
* Receive outpatient medical services
Exclusion Criteria:
* They do not own a mobile device with internet access.
* They have a history of severe intellectual disability.
* They are unable to operate a mobile device (keyboard or touchscreen).
* Reside in an in-patient setting.
* Adults unable to consent.
* Pregnant women (excluded because pregnancy is not relevant to the study focus).
* Prisoners.
Interventions
OTHER
Medilepsy® Chatbot AI-Enhanced
OTHER
Medilepsy® Chatbot Standard
Conditions
EpilepsySeizure
Locations
Orlando Health Arnold Palmer Hospital
Orlando, Florida 32806
United States
Orlando Health Orlando Regional Medical Center
Orlando, Florida 32806
United States